Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease (Q46902397)

26 December 2017

title

Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease (English)

1 reference

26 December 2017

1 reference

26 December 2017

Neil C. Thomson

1 reference

26 December 2017

author name string

Neil C Barnes

1 reference

26 December 2017

Yu-Sheng Qiu

1 reference

26 December 2017

Debbie Parker

1 reference

26 December 2017

Peter A Davis

1 reference

26 December 2017

Jie Zhu

1 reference

26 December 2017

Malcolm Johnson

1 reference

26 December 2017

Peter K Jeffery

1 reference

26 December 2017

SCO30005 Study Group

1 reference

26 December 2017

language of work or name

English

0 references

publication date

19 January 2006

1 reference

26 December 2017

American Journal of Respiratory and Critical Care Medicine

published in

1 reference

26 December 2017

volume

173

1 reference

26 December 2017

issue

1 reference

26 December 2017

page(s)

736-743

1 reference

26 December 2017

Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200508-1321OC

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200508-1321OC

Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200508-1321OC

Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200508-1321OC

Ongoing airway inflammation in patients with COPD who do not currently smoke

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200508-1321OC

Comparison of the structural and inflammatory features of COPD and asthma. Giles F. Filley Lecture

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200508-1321OC

The nature of small-airway obstruction in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200508-1321OC

Amplification of inflammation in emphysema and its association with latent adenoviral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200508-1321OC

Airway inflammation in severe chronic obstructive pulmonary disease: relationship with lung function and radiologic emphysema

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200508-1321OC

Role of sputum differential cell count in detecting airway inflammation in patients with chronic bronchial asthma or COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200508-1321OC

Bronchial inflammation in chronic bronchitis assessed by measurement of cell products in bronchial lavage fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200508-1321OC

Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200508-1321OC

Acute and chronic airway responses to viral infection: implications for asthma and chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200508-1321OC

Time course of cigarette smoke-induced pulmonary inflammation in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200508-1321OC

Measuring the effectiveness of inhaled corticosteroids for COPD is not easy!

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200508-1321OC

Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200508-1321OC

Exacerbations of Bronchitis: bronchial eosinophilia and gene expression for interleukin-4, interleukin-5, and eosinophil chemoattractants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200508-1321OC

Safety of bronchoscopy, biopsy, and BAL in research patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200508-1321OC

Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200508-1321OC

Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200508-1321OC

Efficacy of theophylline in people with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200508-1321OC

Alveolar epithelial cell chemokine expression triggered by antigen-specific cytolytic CD8(+) T cell recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200508-1321OC

Neutrophils and the pathogenesis of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200508-1321OC

Interferon gamma induction of pulmonary emphysema in the adult murine lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200508-1321OC

The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200508-1321OC

Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200508-1321OC

Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200508-1321OC

Alternative mechanisms for long-acting beta(2)-adrenergic agonists in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200508-1321OC

Effects of salmeterol on mucosal inflammation in asthma: a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200508-1321OC

Formoterol attenuates neutrophilic airway inflammation in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200508-1321OC

Molecular interactions between glucocorticoids and long-acting beta2-agonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200508-1321OC

The prediction of small airway dimensions using computed tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200508-1321OC

Dissociation of lung function and airway inflammation in chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200508-1321OC

The TORCH (towards a revolution in COPD health) survival study protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200508-1321OC

Differences in Airway Inflammation in Patients with Fixed Airflow Obstruction Due to Asthma or Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200508-1321OC

10.1164/RCCM.200508-1321OC

21 January 2018

Identifiers

DOI

1 reference

26 December 2017

1 reference

26 December 2017